Top 5 Target	Count

ER(Estrogen receptors)	1
GABAB receptor(Gamma-Aminobutyric Acid B Receptor)	1
GnRHR(Gonadotropin-releasing hormone receptor)	1
β2-adrenergic receptor(Beta-2 adrenergic receptor)	1
HTR3(5-hydroxytryptamine receptors, ionotropic (HTR3))	1

Drugs associated with Ningbo Team Pharm Co. Ltd.

Elagolix Sodium

Target

GnRHR

Mechanism

GnRHR antagonists

Active Org.

AbbVie, Inc. [+3]

Originator Org.

Neurocrine Biosciences, Inc.

Active Indication

Pain [+7]

Inactive Indication

Menopausal symptoms [+1]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

United States

First Approval Date23 Jul 2018

Formoterol Fumarate

Target

β2-adrenergic receptor

Mechanism

β2-adrenergic receptor agonists

Active Org.

AstraZeneca UK Ltd. [+4]

Originator Org.

Novartis AG

Active Indication

Asthma [+3]

Inactive Indication

airway disease [+4]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

United States

First Approval Date16 Feb 2001

Toremifene Citrate

Target

Mechanism

ERs modulators

Active Org.

Orion Oyj [+4]

Originator Org.

Orion Co., Ltd.

Active Indication

Estrogen receptor-negative breast cancer [+3]

Inactive Indication

Fractures, Bone [+7]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

Japan

First Approval Date31 Mar 1995

Clinical Trials associated with Ningbo Team Pharm Co. Ltd.

CTR20251893

/ CompletedNot Applicable

苯磺酸左氨氯地平片在健康受试者中单中心、随机、开放、单剂量、双周期、双交叉空腹和餐后状态下的生物等效性试验

[Translation] A single-center, randomized, open-label, single-dose, two-period, double-crossover bioequivalence study of levamlodipine besylate tablets in healthy subjects under fasting and fed conditions

主要目的比较空腹和餐后给药条件下，福安药业集团宁波天衡制药有限公司提供的苯磺酸左氨氯地平片（5mg(按C20H25CIN2O5计)）与辉瑞制药有限公司持证的苯磺酸氨氯地平片（10mg，商品名：络活喜（Norvasc））在健康成年人群中吸收程度和速度的差异，评价其生物等效性。次要目的评价空腹和餐后给药条件下，福安药业集团宁波天衡制药有限公司提供的苯磺酸左氨氯地平片（5mg(按C20H25CIN2O5计)）与辉瑞制药有限公司持证的苯磺酸氨氯地平片（10mg，商品名：络活喜（Norvasc））在健康成年人群中的安全性。

[Translation]

Main purpose To compare the differences in absorption extent and rate of levamlodipine besylate tablets (5 mg (calculated as C20H25CIN2O5)) provided by Ningbo Tianheng Pharmaceutical Co., Ltd. of Fu'an Pharmaceutical Group and amlodipine besylate tablets (10 mg, trade name: Norvasc) certified by Pfizer Pharmaceuticals Co., Ltd. in healthy adults under fasting and postprandial administration conditions, and to evaluate their bioequivalence. Secondary purpose To evaluate the safety of levamlodipine besylate tablets (5 mg (calculated as C20H25CIN2O5)) provided by Ningbo Tianheng Pharmaceutical Co., Ltd. of Fu'an Pharmaceutical Group and amlodipine besylate tablets (10 mg, trade name: Norvasc) certified by Pfizer Pharmaceuticals Co., Ltd. in healthy adults under fasting and postprandial administration conditions.

Start Date05 Jul 2025

Sponsor / Collaborator

Ningbo Team Pharm Co. Ltd.

CTR20251898

/ Active, not recruitingNot Applicable

雷诺嗪缓释片在中国健康成年参与者中随机、开放、单剂量、交叉、空腹和餐后状态下的生物等效性试验

[Translation] A randomized, open-label, single-dose, crossover, fasting and fed bioequivalence study of ranolazine extended-release tablets in healthy Chinese adult participants

主要目的：以福安药业集团宁波天衡制药有限公司生产的雷诺嗪缓释片（500mg）为受试制剂，以 Menarini International Operations Luxembourg S.A.持有的雷诺嗪缓释片（商品名：Ranexa，规格：500mg）为参比制剂，进行生物等效性试验，比较两种制剂在空腹和餐后条件下单次给药的生物等效性。次要目的：评估单剂口服受试制剂（雷诺嗪缓释片，T）和参比制剂（Ranexa，R）在中国健康成年参与者中的安全性。

[Translation]

Primary objective: The bioequivalence study was conducted using Ranolazine sustained-release tablets (500 mg) produced by Ningbo Tianheng Pharmaceutical Co., Ltd. of Fu'an Pharmaceutical Group as the test formulation and Ranolazine sustained-release tablets (trade name: Ranexa, specification: 500 mg) held by Menarini International Operations Luxembourg S.A. as the reference formulation to compare the bioequivalence of the two formulations under fasting and fed conditions after a single dose. Secondary objective: Evaluate the safety of a single oral dose of the test formulation (Ranexa sustained-release tablets, T) and the reference formulation (Ranexa, R) in healthy adult participants in China.

Start Date10 Jun 2025

Sponsor / Collaborator

Ningbo Team Pharm Co. Ltd.

CTR20243329

/ CompletedNot Applicable

硫酸艾沙康唑胶囊在中国健康受试者中的生物等效性试验

[Translation] Bioequivalence study of isavuconazole sulfate capsules in Chinese healthy volunteers

主要研究目的：以福安药业集团庆余堂制药有限公司持有的硫酸艾沙康唑胶囊（100mg，按C22H17F2N5OS计）为受试制剂（T），按有关生物等效性试验的规定，以Pfizer Australia Pty Ltd.持证的硫酸艾沙康唑胶囊（100mg，按C22H17F2N5OS计）为参比制剂（R）进行生物等效性试验。次要研究目的：观察受试制剂和参比制剂硫酸艾沙康唑胶囊（100mg，按C22H17F2N5OS计）在健康受试者中的安全性。

[Translation]

Main study objectives: The isavuconazole sulfate capsules (100 mg, calculated as C22H17F2N5OS) held by Qingyutang Pharmaceutical Co., Ltd. of Fu'an Pharmaceutical Group were used as the test preparation (T), and the isavuconazole sulfate capsules (100 mg, calculated as C22H17F2N5OS) certified by Pfizer Australia Pty Ltd. were used as the reference preparation (R) for bioequivalence test according to the relevant provisions of bioequivalence test. Secondary study objectives: Observe the safety of the test preparation and the reference preparation isavuconazole sulfate capsules (100 mg, calculated as C22H17F2N5OS) in healthy subjects.

Start Date14 Sep 2024

Sponsor / Collaborator

Ningbo Team Pharm Co. Ltd.

100 Clinical Results associated with Ningbo Team Pharm Co. Ltd.

0 Patents (Medical) associated with Ningbo Team Pharm Co. Ltd.

Literatures (Medical) associated with Ningbo Team Pharm Co. Ltd.

18 Aug 2025·Bioanalysis

Pharmacokinetic study of isavuconazonium in human plasma measured by HPLC-MS/MS and its use in healthy Chinese subjects

Article

Author: Yu, Yonghua ; Qiu, Linlin ; Lin, Jie ; Su, Yuchen ; Kong, Yifu ; Chen, Yifang ; Zhou, Yanli

AIMS:

To establish a rapid, sensitive HPLC-MS/MS method for quantifying isavuconazonium in human plasma and characterize its pharmacokinetics in healthy Chinese subjects under fasting and postprandial conditions.

MATERIALS & METHODS:

Plasma samples were processed via acetonitrile protein precipitation. Separation was performed on an LC-20ADXR Plus C18 column with gradient elution (0.01% formic acid/acetonitrile). Detection used a Triple Quad 4500 mass spectrometer with MRM; isavuconazole-d4 was the internal standard. The method was validated, then applied to a crossover study in 32 healthy subjects (fasting vs. postprandial).

RESULTS:

The method showed good linearity (4-4000 ng/mL, R² ≥0.9801) with LLOQ 4 ng/mL. Stability was confirmed under various conditions (e.g. 53 days at -20°C, 66 days at -80°C). Pharmacokinetic results revealed food delayed Tmax (2.5 vs. 5.0 h) and reduced Cmax (1929.68 vs. 1300.17 ng/mL) but did not affect AUC_0-t.

CONCLUSIONS:

The validated HPLC-MS/MS method is rapid and reliable for therapeutic drug monitoring. Food affects absorption but not total exposure, guiding clinical dosing in Chinese populations.

03 Jul 2025·Bioanalysis

A validated method for the determination of doxofylline and its pharmacokinetic application in healthy volunteers

Article

Author: Liu, Danrui ; Luo, Kaiwei ; Hu, Yu ; Zhao, Hangyu ; Zhang, Huina ; Dai, Menglong ; Yu, Yonghua

BACKGROUND:

Current HPLC-based methods for doxofylline analysis lack speed and precision. A rapid, specific, and sensitive UPLC-MS/MS method was developed for the determination of doxofylline in this study.

RESEARCH DESIGN AND METHODS:

This method was fully validated and doxophylline-d4 was used as an internal standard. A Kinetex-C18 column (EVO 100Å, 50 × 2.1 mm, 5 μm) was used for the separation procedure, with mobile phases consisting of 0.3% formic acid (A) and 90% acetonitrile solution with 0.3% formic acid (B). The total runtime of the gradient elution procedure was 2.6 minutes. The mass spectrometry analysis was carried out employing a multiple reaction monitoring model and using the transitions of m/z 267.000→181.000 for doxofylline and m/z 271.200→181.100 for the internal standard.

RESULTS:

The linear range of detection for doxophylline was between 20.0 to 16,000 ng/mL. The intra-batch accuracy deviations of each concentration level ranged from -8.0% to 2.5%, while the intra-batch precisions ranged from 1.3% to 9.0%. And the inter-batch accuracy deviations were -5.8% ~0.8%, while the inter-batch precisions were 2.2% ~7.0%.

CONCLUSIONS:

This method was applied to pharmacokinetic clinical trials of single oral administration of doxophylline tablets successfully.

CLINICAL TRIAL REGISTRATION:

www.clinicaltrials.gov identifier is CTR20240006 and CTR20233665.

19 May 2025·Bioanalysis

LC-MS/MS determination of trazodone in human plasma and its pharmacokinetic study in healthy Chinese

Article

Author: Lin, Jie ; Zhang, Shengshuo ; Yu, Yonghua ; Luo, Kaiwei ; Liu, Danrui ; Cheng, Qunan ; Zhang, Xin

AIMS:

This study aimed to establish a robust LC-MS/MS method for quantifying trazodone in human plasma and investigate its pharmacokinetic profile in healthy Chinese subjects under fasting and fed conditions.

MATERIALS & METHODS:

A validated LC-MS/MS method using protein precipitation was applied to analyze trazodone in 68 healthy subjects (34 fasting/34 fed), with full method validation performed.

RESULTS:

This method exhibited high selectivity, precision, and accuracy. The results showed good linearity in the range of 5-3000 ng/mL and matrix effect results showed no matrix interference. The pharmacokinetic data revealed notable differences between the fasting and postprandial states.

CONCLUSIONS:

The validated LC-MS/MS method proved reliable for trazodone quantification. The observed food effects on absorption suggest clinical dosing should consider administration conditions to ensure optimal therapeutic outcomes.

100 Deals associated with Ningbo Team Pharm Co. Ltd.

100 Translational Medicine associated with Ningbo Team Pharm Co. Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 22 Dec 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1

Approved

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Ondansetron Hydrochloride ( HTR3 )	Radiation-induced nausea and vomiting More	Approved
Formoterol Fumarate ( β2-adrenergic receptor )	Asthma More	Approved
Baclofen ( GABAB receptor )	Muscle Spasticity More	Approved
Toremifene Citrate ( ER )	Breast Cancer More	Approved
Elagolix Sodium ( GnRHR )	Severe pain More	Phase 1

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis